Is NewLimit really worth $3.1B before human trials?
In our updated market reports, you will find everything you need
SUMMARY
NewLimit is probably not worth $3.1 billion on the evidence available before human trials, although the valuation is understandable as a high-risk bet on an unusually advanced longevity platform.
The price rose so quickly because the company moved its first liver program from open-ended discovery to a selected preclinical candidate much earlier than investors expected. That is real progress, but it does not remove the large gap between animal results and a useful human medicine.
NewLimit is no longer just testing whether old cells can be made to look younger. It has optimized an mRNA payload, improved liver-cell targeting, scaled manufacturing and built assays that check whether large batches still produce the intended biological effect.
The public liver package is unusually broad for a preclinical program. NewLimit reports improvements in regeneration, resistance to injury, metabolism and gene expression, with some effects persisting after the treatment itself had cleared.
The evidence is still difficult for outsiders to audit. The company has not disclosed the factors in its lead candidate or released the complete dose-response data, animal numbers, statistical analysis and independent replication needed for a full scientific judgment.
Most of the valuation therefore comes from the platform, not the first drug alone. Investors are betting that NewLimit can repeat the same discovery process across liver, vascular, immune and eventually other tissues.
The liver is a sensible first target because lipid nanoparticles already deliver RNA there, the organ regenerates naturally and early biological effects can be measured more clearly than vague claims about whole-body rejuvenation.
The biggest technical risk is not simply whether the therapy changes cells. It must change enough hepatocytes in the intended direction without causing inflammation, loss of cell identity, abnormal growth or delayed cancer risk.
A successful alcohol-related liver-disease treatment could become a major product, but it probably would not justify the whole valuation by itself. The larger outcome requires expansion into MASH, broader metabolic disease, additional organs or several of those markets at once.
Series C investors need far more than a safe Phase 1 study. After future dilution and years of development, NewLimit likely needs to become a $15 billion to $25 billion company for the round to deliver a venture-style return.
The valuation would begin to look cheap if human data showed accurate liver delivery, a clear dose-related biological effect and durable improvement after the mRNA disappears. A second clinical candidate produced by the same platform would strengthen the case even more.
For now, NewLimit has earned a place among the most credible longevity biotechs, but investors are paying today for a meaningful share of success that has not yet been demonstrated in people.
Is NewLimit really worth $3.1B before human trials?
Mostly no: NewLimit has earned its place among the most credible longevity biotechs, but the $3.1 billion valuation currently runs ahead of what its publicly available evidence can support.
We are not looking at a vague anti-aging startup selling supplements or biological-age tests. NewLimit has selected a defined medicine, improved its delivery, scaled production, built functional manufacturing tests and produced a broad animal package. Its AI-guided system has also generated useful payloads across more than one cell type.
The wider field has advanced too. Partial reprogramming repeatedly changes age-related biology in animals, and the first human trial is now active. Liver-targeted RNA delivery already has regulatory precedent. These are substantial foundations.
The gap remains human evidence. NewLimit has not shown that its treatment reaches the right human cells, changes them safely, improves liver function or produces a clinical benefit. Outsiders also cannot inspect the complete candidate dataset.
Our final judgment is that the valuation is understandable as a high-risk venture bet and premature as a risk-adjusted valuation of the assets already proven. It assumes that the liver candidate will show useful human biology and that the same discovery engine will eventually produce several medicines.
NewLimit could become worth far more. Investors are already paying for a meaningful share of that success before the hardest evidence exists.
If you want more recent data on this point, please see our latest cellular reprogramming market report.
Why did NewLimit’s valuation rise so quickly?
NewLimit reached a $3.1 billion valuation because investors saw its first liver medicine arrive years earlier than expected and decided the company had crossed from open-ended research into drug development.
The repricing was extreme. NewLimit raised $130 million at an $810 million valuation in 2025. Five months later, it added $45 million through financing capped at $1.62 billion. Its latest $435 million Series C then valued the company at $3.1 billion.
That amounts to a 3.8-fold jump from the Series B valuation in a little over a year. The increase looks even more striking because NewLimit still has no human data and no approved product.
The explanation lies in its timeline. When the Series B closed, management thought finding a clinic-ready medicine could still take several years. A combination of transcription factors then performed far better than expected in its liver experiments. NewLimit selected it as a preclinical candidate and now plans to begin human testing next year.
The company also completed work that investors would expect before a drug reaches the clinic. It improved how accurately the therapy reaches liver cells, started producing larger batches and developed tests to check whether each batch has the intended biological effect.
We should still be precise about what “worth” means. The $3.1 billion figure is the price negotiated for preferred shares in a private financing round. It shows what a group of investors accepted. It does not tell us what a pharmaceutical company would pay to acquire NewLimit today, especially since the protections attached to the new shares have not been disclosed.
| Financing | Capital raised | Price reference | What had changed |
|---|---|---|---|
| Series B | $130M | $810M valuation | Liver program moving toward development |
| Later financing | $45M | $1.62B valuation cap | Clinical timeline becoming clearer |
| Series C | $435M | $3.1B valuation | Candidate selected and trial brought forward |
Are investors buying one liver drug or a whole platform?
Currently, NewLimit has one actual drug candidate, while nearly all the value above a normal preclinical biotech valuation comes from the hope that its discovery system can produce many more.
The immediate product is fairly specific. NewLimit plans to package fewer than ten transcription-factor instructions as mRNA inside lipid nanoparticles. After reaching liver cells, those instructions temporarily change which genes the cells use, with the aim of restoring functions that weaken with age.
Behind that candidate sits a much wider ambition. NewLimit is also working on the endothelial cells that line blood vessels and on T cells involved in the immune system. Its website presents metabolism, vascular health and immunity as the first three branches of a broader pipeline.
That distinction drives the valuation. One experimental liver treatment for alcohol-related disease would need exceptional clinical results and a large commercial expansion to support billions of dollars. A repeatable system that generates medicines for the liver, kidney, immune system and other organs could support a far larger company.
Today, investors are paying for both possibilities. Only the liver program has reached candidate status, so most of the platform value remains a forecast.
Is NewLimit already building a real drug?
Yes, NewLimit is now doing the unglamorous development work required for a real drug rather than stopping at promising experiments in old cells.
Its candidate first emerged from a model in which old human liver cells were placed inside animal livers. The selected treatment reportedly made those human cells express younger patterns of genes and regenerate more effectively after injury.
NewLimit then adjusted the RNA sequence and delivery system. According to its year-end research report, the changes improved potency by 1.6 times and increased selectivity for hepatocytes eightfold. The final sequence designs were more than 100 times more active in the target liver cells than in the off-target cells tested.
The manufacturing numbers make the shift easier to understand. An early experiment might use less than one milligram of material. NewLimit expects pivotal animal-safety studies to require more than 100 milligrams and its first clinical trial to require more than 1,000 milligrams. In its latest update, the company said it had already made batches over 120 times larger than its earlier batches.
It also built a cell-based test that checks whether each batch produces the intended biological effect. Measuring the amount of RNA is relatively easy. Showing that the finished product still changes cells correctly after a large manufacturing run is harder.
Those achievements place NewLimit firmly in preclinical development. Regulatory clearance, final toxicology work and human dosing still lie ahead.
If you want more recent data on this point, please see our latest cellular reprogramming market report.
Do NewLimit’s liver results look unusually strong?
Yes, NewLimit’s liver package looks stronger than the usual claim that a treatment made old cells appear younger, because the same candidate improved several different functions.
The company reports that treated old livers regenerated more effectively after surgical injury and suffered less damage during an alcohol-containing diet. In another experiment, old mice normally remained heavily sedated for hours after consuming alcohol, while treated animals recovered more like younger mice.
The mouse behavior makes a good video, although it would be weak evidence on its own. The more useful observation is that the candidate appears to affect regeneration, resistance to injury, metabolism and gene expression together. That pattern fits NewLimit’s claim that it is changing the cell’s broader state rather than modifying one narrow pathway.
The effect also appears to last beyond the presence of the medicine. NewLimit treated animals, waited for the RNA therapy to clear and then exposed them to a damaging diet. The animals reportedly retained greater resilience.
That could eventually allow less frequent dosing. For now, the public results do not show how long the effect lasted, how large each study was or how consistently individual animals responded.
The package is impressive and incomplete. It is unusually broad for a preclinical program, but the strongest evidence still comes from NewLimit itself.
Can outsiders verify NewLimit’s best results?
Only partly, because NewLimit has published plenty about its methods but has not released enough candidate-level data for an independent scientific judgment.
The company explains how its screening system works, how its AI chooses experiments and which functions improved in its liver models. It also publishes progress reports far more frequently than most private biotechs.
The missing details are important. NewLimit has not disclosed the transcription factors in its lead candidate. We could not find a peer-reviewed paper presenting the complete liver dataset, detailed dose-response results, animal numbers, full statistical analysis or independent replication of the selected medicine.
Its investors probably reviewed far more material during due diligence. Founders Fund, Kleiner Perkins, Thrive Capital, Greenoaks and Eli Lilly Ventures had the resources to examine raw data, patents, manufacturing records and toxicology plans.
That gives NewLimit meaningful private validation. Public readers are left with a different level of certainty. Investors decided the private evidence justified a risky purchase; outside scientists still lack the information required to reproduce the central result.
Has age reprogramming actually worked in a person?
No. Age reprogramming has now entered human testing, but nobody has shown that it can safely make a person healthier.
The field recently reached a historic milestone when Life Biosciences dosed the first participant with ER-100. That treatment uses three well-known reprogramming factors, OCT4, SOX2 and KLF4, to target damaged cells in the eye. The Phase 1 study covers people with glaucoma or another form of optic-nerve damage.
This development is relevant to NewLimit because the FDA has now accepted that controlled partial reprogramming can be tested in humans. The category has moved beyond mouse experiments and future trial plans.
The comparison quickly reaches its limits. Life Biosciences injects a viral gene therapy locally into the eye and controls expression of the factors. NewLimit intends to send a temporary mRNA treatment through the bloodstream toward a much larger internal organ. The payload, delivery method, target cells and dosing schedule are different.
A clean result from ER-100 would make regulators and doctors more comfortable with the general idea. It would say little about whether NewLimit’s liver candidate reaches the correct cells or remains safe after repeated systemic dosing.
As of now, the first human experiment has begun. There is still no human proof that partial reprogramming improves tissue function or disease.
Could NewLimit’s treatment cause cancer or confuse liver cells?
Yes, cancer and loss of cell identity remain serious risks whenever a medicine deliberately rewrites the instructions that control how cells behave.
Classic reprogramming can push a mature cell back toward a stem-cell-like state. Earlier mouse experiments using the four Yamanaka factors produced abnormal tissue and tumors when expression continued too long. Reviews of the field still describe preserving cell identity as one of its central unsolved problems.
NewLimit has designed around that danger. It uses temporary mRNA, so the transcription factors should disappear rather than remain permanently active. It searches for alternative combinations instead of automatically using all four Yamanaka factors. The company also screens for payloads that preserve liver-cell identity while restoring younger behavior.
In its animal studies, NewLimit says high doses produced neither visible liver toxicity nor neoplasia. That is reassuring preclinical evidence.
The harder risks may take longer to appear. Repeated treatment could change a small population of cells incorrectly, stimulate a precancerous cell, affect another organ or create damage that only becomes visible months later. A mouse study with a limited follow-up period cannot close those questions.
Transient mRNA gives doctors more control than permanent genetic modification. Even so, the treatment is intervening in biology powerful enough to create both regeneration and uncontrolled growth.
If you want more recent data on this point, please see our latest cellular reprogramming market report.
Why is NewLimit starting with damaged livers?
The liver gives NewLimit its clearest route into humans because RNA delivery already works there, liver function is easy to measure and serious disease can justify an infusion-based treatment.
Lipid nanoparticles naturally tend to reach the liver. The FDA approved Onpattro in 2018 as an intravenous RNA medicine delivered to hepatocytes every three weeks. NewLimit must solve a more complex biological problem, but it does not need to prove from scratch that lipid nanoparticles can carry RNA into human liver cells.
The organ is also naturally regenerative. Researchers can measure whether treatment changes liver enzymes, fat accumulation, scarring, metabolism, regeneration and resistance to injury. Those are more practical early endpoints than vague claims about energy or whole-body youth.
Starting with a diagnosed disease also gives NewLimit a regulatory path. The FDA does not currently approve drugs for “aging” itself. A company must first show that its treatment helps people with a recognized medical condition.
The latest clinical plan begins broadly with patients who have fatty liver from several causes. Later development would focus more closely on alcohol-related liver disease. That gives NewLimit room to learn where the treatment performs best before committing to one final market.
Will Phase 1 tell us whether NewLimit works?
No. NewLimit’s first human trial should reveal whether the treatment can be given safely and changes the intended biology, while convincing evidence of patient benefit will probably take longer.
The first questions are basic but decisive. Does the lipid nanoparticle reach human hepatocytes? How much drug is needed? Do the transcription factors appear for the expected amount of time? Does liver biology move in the intended direction? Do patients experience inflammation, toxicity or unexpected changes in other tissues?
A clean result would remove a major part of the uncertainty surrounding NewLimit. A clean result without measurable target engagement would be much less valuable. The company needs evidence that the medicine does something specific, not merely that the first few doses caused no obvious harm.
Phase 2 is likely to be the harder test. A recent Nature Communications analysis of more than 20,000 clinical-development programs found that Phase 2 remained the stage with the lowest progression rate. This is where a plausible mechanism must start producing a meaningful effect in real patients.
Older industry benchmarks from BIO, Informa and QLS estimated that fewer than 8% of drugs entering Phase 1 eventually reached approval. The exact probability for NewLimit cannot be calculated from those averages because partial reprogramming has no useful clinical history. They still show how much risk remains after the first patient is dosed.
| Development step | What NewLimit needs to show | What remains afterward |
|---|---|---|
| Phase 1 | Initial safety, delivery and biological activity | Whether the change helps patients |
| Phase 2 | Clear proof of concept in liver disease | Confirmation in a larger population |
| Phase 3 | Reliable clinical benefit and acceptable risk | Regulatory review and commercial launch |
| Approval | A treatment can legally be sold | Adoption, reimbursement and long-term safety |
Can alcohol-related liver disease support a multibillion-dollar drug?
Yes, alcohol-related liver disease can support a valuable medicine, although the market alone probably cannot carry NewLimit’s full valuation without expansion into wider liver and metabolic conditions.
A recent JAMA review described alcohol-related liver disease as the leading cause of liver-related illness and death and the most common reason for liver transplantation in the United States and Europe. US mortality rose from 6.7 deaths per 100,000 people in 1999 to 12.5 in 2022.
Treatment remains limited. Stopping alcohol use can slow or reverse early disease, but advanced cases may progress toward cirrhosis, liver failure and transplantation. A drug that restores the liver’s ability to recover from damage would address a real clinical gap.
The adjacent MASH market shows how quickly demand can develop for a useful liver treatment. Madrigal’s Rezdiffra generated $958 million during its first full year on the market. In its latest reported quarter, sales reached $311 million and more than 42,000 patients were taking the drug. Madrigal is currently valued at roughly $15.8 billion.
NewLimit cannot assume a similar result. Rezdiffra has human efficacy data, regulatory approval and access to a very large population with metabolic liver disease. NewLimit still needs to determine which patients should receive its therapy, how advanced their disease should be and how long treatment should continue.
A successful alcohol-related liver drug could become a blockbuster. Reaching the larger valuation outcome probably requires MASH, metabolic syndrome, additional organs or all three.
If you want more recent data on this point, please see our latest cellular reprogramming market report.
Will monthly IV infusions stop NewLimit from becoming a mass-market anti-aging drug?
Yes, monthly intravenous infusions would sharply limit NewLimit’s preventive-aging market, even if they remain acceptable for patients with serious liver disease.
A patient facing progressive liver damage may willingly visit an infusion center every month. The benefit can justify the travel, monitoring and clinical staff involved.
The calculation changes for someone who currently feels healthy. Millions of middle-aged adults are unlikely to accept recurring infusions for a theoretical reduction in future age-related decline. Regulators would also demand an exceptionally clean safety profile because those people face no immediate medical emergency.
NewLimit hopes the treatment’s biological effect will last long enough to reduce dosing frequency. Its animal work suggests that some resilience remains after the medicine has cleared, although we do not yet know whether the same persistence will appear in humans.
The first product can still work commercially with monthly dosing. The much larger dream of broadly preserving health will need longer-lasting effects, easier administration or a patient population willing to tolerate a medical procedure for prevention.
Is NewLimit’s AI actually hard to copy?
NewLimit’s moat is real, but the hardest part to copy is its private biological dataset and experimental system rather than the AI model alone.
Its Ambrosia system chooses combinations of transcription factors that might make old cells behave more like young ones. That is a huge search problem: the company estimates more than 10^16 plausible combinations.
NewLimit then tests thousands of those combinations through RESTORE-seq. Each cell receives a barcoded payload, allowing researchers to connect a particular transcription-factor combination with changes in gene expression and cellular function.
The first disclosed Ambrosia dataset included 6,503 combinations tested across 3.6 million human T cells from several donors. The model performed better than simpler baselines, and NewLimit later reported that using Ambrosia inside its experimental loop more than doubled the number of useful discoveries per dollar.
Lately, the platform has started showing limited transfer between programs. NewLimit’s latest update said a model trained across several cell types matched its previous endothelial prediction performance while using more than three times less endothelial data. The same update reported five payloads that improved both youthful gene expression and regenerative function in old endothelial cells.
A rival could reproduce the general machine-learning techniques. Rebuilding millions of proprietary cellular measurements, delivery systems, humanized animal models and failed experiments would take far longer.
The moat becomes truly valuable only when predictions survive clinical testing. At present, Ambrosia has improved NewLimit’s research productivity. Human data will determine whether it improves drug-development productivity.
Has NewLimit really moved faster than normal biotech?
NewLimit has moved unusually fast from building a laboratory to selecting a drug candidate, even though the slower and more failure-prone clinical phase is only beginning.
At the start of 2023, NewLimit had not completed its first major screens or built its first AI system. By the end of 2025, it reported more than 600 payloads that made old cells look younger, 36 that restored function in cells and 16 that improved disease models in animals. One had become a formal preclinical candidate.
The company originally thought reaching that point would take at least five years. It says it did so after roughly three years of operations.
Its later programs also appear to be getting faster. NewLimit transferred its screening tools to endothelial cells without redesigning the core system, built kidney-delivery tools and found functional payloads within months of launching the vascular program.
Those results suggest more than one lucky liver experiment. They show that NewLimit can repeatedly set up large screens, find candidates and move them into tougher functional tests.
The speed advantage currently applies to discovery. Toxicology, regulatory discussions, patient recruitment and long-term follow-up will not move simply because the company’s AI generates candidates faster.
Does Lilly’s investment prove NewLimit’s science is good?
No. Eli Lilly Ventures’ participation strengthens NewLimit’s credibility but falls well short of pharmaceutical validation for the drug itself.
The latest round included Founders Fund, Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract Ventures, Human Capital and Eli Lilly Ventures. Several were existing investors that chose to invest again at a much higher price.
Repeated investment carries some weight. Those firms could compare NewLimit’s actual progress with the promises made during earlier rounds. Lilly also understands metabolic disease, RNA delivery and large clinical programs better than a generalist technology investor.
Still, Lilly purchased equity. It has not publicly licensed the liver candidate, agreed to co-develop it, paid clinical milestones or secured commercial rights. Those deals normally involve a much more direct judgment about an individual drug.
The investor list tells us that sophisticated groups found the private evidence compelling enough to accept large financial risk. It does not tell us that NewLimit has already met the scientific standard required for a partnership or acquisition.
What kind of company do Series C investors need NewLimit to become?
Series C investors probably need NewLimit to become a $15 billion to $25 billion company for the round to generate the type of return that compensates for preclinical biotech risk.
At the announced post-money price, the $435 million investment represents roughly 14% of NewLimit before later dilution. A future $5 billion value would turn that stake into about $702 million, only 1.6 times the original investment. At $10 billion, the gross multiple would be about 3.2 times.
Future fundraising, employee equity and the many years required to reach approval will reduce the effective return. A single moderately successful liver drug may leave the newest investors with an ordinary outcome.
Biotech history also gives us reasons to distrust large platform premiums. Sana Biotechnology entered the public market while preclinical at a fully diluted value near $4.9 billion. Today, it is worth around $880 million. Prime Medicine went public before human trials at roughly $1.6 billion and is currently worth about $522 million.
Those companies may still produce successful medicines. Their falling market values show how quickly investors discount a platform when development takes longer than expected or clinical proof remains distant.
The longevity comparison is equally revealing. Retro Biosciences recently announced financing at a $1.8 billion pre-money valuation. Altos Labs launched with $3 billion in funding, although that was capital raised rather than a disclosed valuation. NewLimit now sits near the top of its field despite having no human data.
Investors have priced in much more than a successful Phase 1 study. They need a large liver franchise, proof that the platform works across organs or both.
| Future company value | Approximate Series C stake value before dilution | Gross return on $435M |
|---|---|---|
| $5B | $702M | 1.6x |
| $10B | $1.40B | 3.2x |
| $15B | $2.11B | 4.8x |
| $25B | $3.51B | 8.1x |
If you want more recent data on this point, please see our latest cellular reprogramming market report.
What would make NewLimit’s valuation look cheap?
Three human results would make NewLimit’s current valuation look far more reasonable: accurate liver delivery, controlled cellular reprogramming and a durable improvement in function.
First, the therapy must reach enough hepatocytes while largely avoiding other cells. NewLimit has strong animal specificity data, but human distribution can differ.
Second, the treatment must create a measurable and dose-related biological change. Doctors should see the intended liver-cell program move in a younger direction without signs of stress, inflammation or loss of identity.
Third, the effect should last after the mRNA disappears. A durable cellular change could reduce treatment frequency and make the economics far more attractive.
Safety will remain non-negotiable. No uncontrolled cell growth, suspicious tissue changes or serious immune reactions can emerge as doses increase.
A second clinical candidate would then carry more value. Success in the liver would show that NewLimit can create one drug. A vascular or immune candidate following the same path would show that the platform itself deserves a premium.
Strong animal data caused the latest repricing. Strong human pharmacology would justify it much more convincingly.
OUR METHODOLOGY
This analysis tests whether NewLimit’s $3.1 billion private financing valuation is justified before the company has begun human trials. We compare the valuation with the maturity of its lead liver candidate, the strength and public verifiability of its evidence, the repeatability of its discovery platform, the risks remaining before clinical efficacy, the commercial potential of its first indication and the scale of the outcome required to reward Series C investors.
We treat the $3.1 billion figure as the price negotiated for preferred shares in NewLimit’s Series C, not as an acquisition value or a public-market valuation. The undisclosed rights attached to those shares may affect how directly the headline number can be compared with the value of the whole company.
We separate candidate selection from human validation. A selected preclinical candidate, scaled manufacturing process and functional batch assay show that NewLimit is building a real drug, but they do not establish safety, target engagement, efficacy or durable benefit in people.
We also separate the value of the lead liver program from the value of the wider platform. Only the liver program has reached candidate status, while the endothelial, immune and other tissue programs remain evidence that the discovery system may be repeatable rather than proof that it will produce several successful medicines.
Company-reported animal results are assessed according to what they demonstrate directly. Improvements in regeneration, injury resistance, metabolism and gene expression strengthen the preclinical package, but limited disclosure of animal numbers, dose-response data, statistics, follow-up and independent replication reduces the confidence outsiders can place in the result.
Clinical risk is evaluated using relevant precedents rather than treating partial reprogramming as an established drug category. We reviewed the first-in-human ER-100 study, FDA precedent for liver-targeted RNA delivery, broader clinical-development success rates and the known risks of loss of cell identity, abnormal growth and delayed toxicity.
The commercial analysis distinguishes a serious liver-disease product from a mass-market preventive-aging product. Alcohol-related liver disease and adjacent metabolic liver conditions can support a large medicine, while recurring intravenous administration and the safety threshold for healthy people make broad preventive use much harder.
Investor participation is treated as private validation, not as proof of the candidate. Repeat backing from specialist and generalist investors, including Eli Lilly Ventures, suggests that sophisticated parties reviewed substantial non-public evidence. It is still weaker than a licensing, co-development or acquisition agreement tied directly to the liver drug.
The Series C return analysis uses the announced $435 million investment and $3.1 billion post-money valuation to estimate the stake before future dilution. The resulting scenarios are gross illustrations rather than forecasts, because later fundraising, employee equity, development costs, time and financing terms will change the investors’ actual return.
We prioritized first-hand sources and sources containing checkable scientific, clinical or financial information. Key sources include NewLimit’s Series C announcement, its Series B announcement, the later financing update, its 2025 research review, its 2026 progress update, its latest manufacturing and platform update, the ClinicalTrials.gov record for ER-100, Life Biosciences’ first-patient announcement, the FDA’s overview of patisiran and RNA medicines, the Nature Communications analysis of clinical-development programs, the BIO, Informa and QLS success-rate report, the JAMA review of alcohol-related liver disease, and Madrigal’s first-quarter 2026 Form 10-Q.
Related blog posts
- Which startup looks most promising in reversing cellular aging?
